HOME ·

JUNSHI BIO

JUNSHI BIO (01877.HK): JS207 + JS007 Phase III HCC Doses First Patient
Tags：
JUNSHI BIO01877.HKR&D Progress
2026-10-29
JUNSHI BIO (01877.HK): First Patient Dosed in Phase III Trial of JS203 for r/r DLBCL
Tags：
NewTimeSpaceJUNSHI BIO01877.HK
2026-10-23
Junshi Biosciences (01877.HK): Toripalimab NSCLC Indication Supplemental Application Accepted; Expanded from Stage IIIA-IIIB to Stage II-III
Tags：
JUNSHI BIO01877.HK
2026-07-21
Junshi Biosciences (01877.HK): Signs Licensing Agreement with Fosun Wampo; Receives RMB215 Million Upfront and Up to RMB1.125 Billion Milestones
Tags：
JUNSHI BIO01877.HK
2026-07-01
JUNSHI BIO(01877.HK): 2026 Q1 Report - Profit Attributable to Shareholders stood at loss of CNY 20.56 million, loss narrowed by 91.24% YoY
Tags：
JUNSHI BIO01877.HKnarrow losses
2026-04-28